3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
3
Phase 3
2
Phase NA
1
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
11
Neurofibromatosis 1
9
Melanoma
6
Neurofibroma, Plexiform
5
Pancreatic Neoplasms
3
Lung Neoplasms
3
Colorectal Neoplasms
3
Carcinoma, Hepatocellular
3
Breast Neoplasms
3
Triple Negative Breast Neoplasms
2
Thyroid Neoplasms
2
Thyroid Cancer, Papillary
2
Sarcoma
2
Neurofibrosarcoma
2
Gallbladder Neoplasms
2
Bile Duct Neoplasms
2
Uveal Melanoma
1
Thymoma
1
Small Cell Lung Carcinoma
1
Recurrence
1
Peripheral Nervous System Diseases
1
Non-small Cell Lung Cancer Metastatic
1
Neuroma, Acoustic
1
Neurofibromatosis 2
1
Neuroblastoma
1
Neoplasms, Nerve Tissue
1
Neoplasm Metastasis
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Interventions
Oxaliplatin
67
Capecitabine
60
Fluorouracil
58
Bevacizumab
54
Gemcitabine
51
Paclitaxel
50
Leucovorin
50
Irinotecan
40
Docetaxel
39
Carboplatin
39
Cisplatin
38
pembrolizumab
37
Nivolumab
37
Cetuximab
35
Sunitinib
25
Trastuzumab
24
Radiosurgery
24
Radiotherapy
21
Doxorubicin
21
Cyclophosphamide
21
Panitumumab
20
Drug Therapy
19
Pemetrexed
18
Everolimus
18
Sorafenib
17
Interleukin-2
16
Fulvestrant
16
Albumin-Bound Paclitaxel
16
atezolizumab
15
Erlotinib Hydrochloride
15
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Neoplasm Metastasis
×
AZD 6244
×
Clear all
NCT01750281
2023-10-24
SELECT-2
AstraZeneca
Phase 2
Completed
212 enrolled
12 charts